DK1322324T3 - Fremgangsmåder til behandling af muskelskader - Google Patents

Fremgangsmåder til behandling af muskelskader

Info

Publication number
DK1322324T3
DK1322324T3 DK01966482.0T DK01966482T DK1322324T3 DK 1322324 T3 DK1322324 T3 DK 1322324T3 DK 01966482 T DK01966482 T DK 01966482T DK 1322324 T3 DK1322324 T3 DK 1322324T3
Authority
DK
Denmark
Prior art keywords
methods
treating muscle
muscle injuries
treating
injured muscle
Prior art date
Application number
DK01966482.0T
Other languages
English (en)
Inventor
Gregory F Brooks
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24721759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1322324(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1322324T3 publication Critical patent/DK1322324T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
DK01966482.0T 2000-10-04 2001-08-31 Fremgangsmåder til behandling af muskelskader DK1322324T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/678,189 US6423319B1 (en) 2000-10-04 2000-10-04 Methods for treating muscle injuries
PCT/US2001/027193 WO2002028425A2 (en) 2000-10-04 2001-08-31 Methods for treating muscle injuries

Publications (1)

Publication Number Publication Date
DK1322324T3 true DK1322324T3 (da) 2010-11-01

Family

ID=24721759

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01966482.0T DK1322324T3 (da) 2000-10-04 2001-08-31 Fremgangsmåder til behandling af muskelskader

Country Status (16)

Country Link
US (4) US6423319B1 (da)
EP (2) EP2174662A3 (da)
JP (2) JP2004518632A (da)
KR (1) KR100873819B1 (da)
CN (2) CN1658897A (da)
AT (1) ATE477816T1 (da)
AU (2) AU8699101A (da)
BR (1) BR0114440A (da)
CA (1) CA2424242C (da)
DE (1) DE60142839D1 (da)
DK (1) DK1322324T3 (da)
ES (1) ES2348862T3 (da)
MX (1) MXPA03002576A (da)
NZ (1) NZ524793A (da)
TW (1) TWI292713B (da)
WO (1) WO2002028425A2 (da)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
CN1585642A (zh) * 2001-11-15 2005-02-23 微观藻类公司 包含3,4－丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
WO2004012674A2 (en) * 2002-08-02 2004-02-12 Nutraceutical Development Corporation Development of muscle mass in a mammal
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
EP1551430A2 (en) * 2002-10-15 2005-07-13 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2005110417A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
WO2005110418A2 (en) * 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
ES2420430T3 (es) 2005-03-03 2013-08-23 Allergan, Inc. Sistema libre de productos de origen animal y procedimiento de purificación de una toxina botulínica
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
AU2006340711C1 (en) 2005-04-05 2013-02-07 Allergan, Inc. Clostridial toxin activity assays
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
WO2006129171A2 (en) * 2005-05-31 2006-12-07 Polydoor Emile Huijsmans Method and medical package for repairing tendons by surgery
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
ES2441961T3 (es) 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
JP5688031B2 (ja) 2009-01-07 2015-03-25 ロバート ジョン ペトレラ， ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療
CA2754423A1 (en) 2009-03-06 2010-09-10 Allergan, Inc. Clostridial toxin to improve ejaculate
EP2480250B1 (en) 2009-09-24 2014-04-16 Allergan, Inc. Compositions comprising botulinum toxin A or B for use in the treatment of osteoporosis
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
WO2012103415A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
AU2012282873B2 (en) 2011-07-08 2016-03-31 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
WO2013012457A1 (en) * 2011-07-20 2013-01-24 Mcginley Joseph C M D Ph D Method of treating and confirming diagnosis of exertional compartment syndrome
US9226954B2 (en) 2011-07-20 2016-01-05 Joseph C. McGinley Method for treating and confirming diagnosis of exertional compartment syndrome
CN103702681A (zh) 2011-07-20 2014-04-02 阿勒根公司 用于治疗脂肪沉积的方法
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9138194B1 (en) 2012-06-27 2015-09-22 Joseph McGinley Apparatus for use to replicate symptoms associated with vascular obstruction secondary to vascular compression
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
ES2612237T3 (es) 2013-03-22 2017-05-12 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, membranas de mucosas y/o uñas
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
CN105567739B (zh) * 2016-02-04 2019-07-12 郑州可尔利尔生物科技有限公司 病毒载体颗粒及其构建方法和应用
CA3018018A1 (en) * 2016-03-25 2017-09-28 Ipsen Biopharm Limited Collecting physical therapy information to enhance treatment efficacy of botulinum toxin
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
WO2018106339A1 (en) * 2016-12-06 2018-06-14 Bonti, Inc. Botulinum neurotoxins for use in tendon repair surgery
CA3057304A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
EP4137149A1 (en) * 2017-04-21 2023-02-22 Bonti, Inc. Initiating neurotoxin treatments
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
JP7186228B2 (ja) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド 非細胞毒性プロテアーゼの注入を案内するための超音波の使用
EP3849585A1 (en) * 2018-09-13 2021-07-21 Allergan, Inc. Methods for treatment of masseter muscle hypertrophy
EP3825689A3 (en) 2018-11-29 2021-09-15 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
US20220096609A1 (en) * 2019-02-06 2022-03-31 Allergan, Inc. Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
CN110710494B (zh) * 2019-10-20 2021-06-11 宋凯 一种眼睛王蛇毒液安全取出装置
JP2022040051A (ja) 2020-08-27 2022-03-10 ユニテックフーズ株式会社 筋損傷回復促進用組成物
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679090A1 (en) 1993-01-15 1995-11-02 Interactive Biologics Associates Method for treating myofascial pain syndrome
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP0735820B1 (en) 1993-12-22 1999-06-23 Zeneca Limited Herbicidal diphenyl ether and nitrogen solution compositions and method
EP0737074B1 (en) * 1993-12-28 2001-08-01 Allergan Sales, Inc. Botulinum toxins for treating hyperhydrosis
US6203794B1 (en) 1994-05-31 2001-03-20 Allergan Sales, Inc. Modification of clostridial toxins for use as transport proteins
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
AU1706400A (en) * 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
NZ520201A (en) * 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DE10131388B4 (de) * 2001-06-28 2004-07-08 Infineon Technologies Ag Integrierter dynamischer Speicher und Verfahren zum Betrieb desselben

Also Published As

Publication number Publication date
CA2424242C (en) 2007-08-07
CA2424242A1 (en) 2002-04-11
MXPA03002576A (es) 2004-04-20
EP1322324B1 (en) 2010-08-18
US7108857B2 (en) 2006-09-19
US6423319B1 (en) 2002-07-23
US7468188B2 (en) 2008-12-23
KR20030043981A (ko) 2003-06-02
CN102078597A (zh) 2011-06-01
TWI292713B (en) 2008-01-21
US20050281846A1 (en) 2005-12-22
WO2002028425A3 (en) 2003-02-27
WO2002028425A2 (en) 2002-04-11
ATE477816T1 (de) 2010-09-15
BR0114440A (pt) 2004-06-15
EP1322324A2 (en) 2003-07-02
NZ524793A (en) 2005-09-30
JP2012229263A (ja) 2012-11-22
US20020192240A1 (en) 2002-12-19
AU8699101A (en) 2002-04-15
KR100873819B1 (ko) 2008-12-11
EP2174662A2 (en) 2010-04-14
JP2004518632A (ja) 2004-06-24
US20070128227A1 (en) 2007-06-07
CN1658897A (zh) 2005-08-24
EP2174662A3 (en) 2010-06-30
AU2001286991B2 (en) 2005-05-19
ES2348862T3 (es) 2010-12-16
DE60142839D1 (de) 2010-09-30
US6955813B2 (en) 2005-10-18

Similar Documents

Publication Publication Date Title
DK1322324T3 (da) Fremgangsmåder til behandling af muskelskader
DK0605501T5 (da) Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese
DK1272207T3 (da) Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
WO2001082961A3 (en) Methods for treating bone tumors
WO2003073994A3 (en) Methods of treating nerve entrapment syndromes
ATE408416T1 (de) Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
BR0312506A (pt) Composições transdérmicas de toxina botulìnica
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
DK1784205T3 (da) Strækmærkebehandling med botulinumtoksin
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BR0315042A (pt) Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
EA199800819A1 (ru) Способ лечения биполярного расстройства
DK1729796T3 (da) Behandling af tryksår
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
EA199800822A1 (ru) Способ лечения избыточной агрессии
EA199800818A1 (ru) Способ лечения бессонницы
UA31156A (uk) Спосіб лікування пневмоентеритів телят
UA36267A (uk) Пристрій для лікування та реабілітації при гострому гематогенному остеомієліті та травматичних пошкодженнях нижніх кінцівок у дітей
RU2001108556A (ru) Способ лечения травм голеностопного сустава